Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Gene,Therapy,For,Cancer,Treatment,Concept,Cancer,Therapy,With,T-cell

Zymeworks Inc. (NASDAQ:ZYME) on Tuesday decided to voluntarily discontinue clinical development of ZW171, a T-cell engager designed to target gynecological, thoracic, and digestive system cancers.

ZW171 is designed to address cancers driven by mesothelin, a well-recognized but historically challenging target.